CR10552A - Metodos para tratar y limitar trastornos fibroticos y queloides - Google Patents

Metodos para tratar y limitar trastornos fibroticos y queloides

Info

Publication number
CR10552A
CR10552A CR10552A CR10552A CR10552A CR 10552 A CR10552 A CR 10552A CR 10552 A CR10552 A CR 10552A CR 10552 A CR10552 A CR 10552A CR 10552 A CR10552 A CR 10552A
Authority
CR
Costa Rica
Prior art keywords
treat
disorders
keloid
methods
limit
Prior art date
Application number
CR10552A
Other languages
English (en)
Inventor
Luciana Biagini Lopes
Elizabeth J Furnish
Charles Robert Flynn
Padmini Komalavilas
Alyssa Panitch
Colleen M Brophy
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Publication of CR10552A publication Critical patent/CR10552A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion proporciona metodos para tratar y/o limitar trastornos fibroticos y/o tratar o limitar cicatrices hipertroficas que comprenden administrar a un individuo que lo necesita una cantidad eficaz para tratar y/o limitar cicatrices seleccionadas del grupo formado por queloides y cicatrices hipertroficas de un polipeptido que comprenden un polipeptido relacionado con HSP20.
CR10552A 2006-07-12 2009-01-09 Metodos para tratar y limitar trastornos fibroticos y queloides CR10552A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83027906P 2006-07-12 2006-07-12
US84904106P 2006-10-02 2006-10-02

Publications (1)

Publication Number Publication Date
CR10552A true CR10552A (es) 2009-05-04

Family

ID=38924094

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10552A CR10552A (es) 2006-07-12 2009-01-09 Metodos para tratar y limitar trastornos fibroticos y queloides

Country Status (13)

Country Link
US (1) US20110028398A1 (es)
EP (1) EP2051727A4 (es)
JP (1) JP5048772B2 (es)
KR (1) KR101267217B1 (es)
AU (1) AU2007272578B2 (es)
BR (1) BRPI0714383A2 (es)
CA (1) CA2657263A1 (es)
CR (1) CR10552A (es)
DO (1) DOP2009000005A (es)
MX (1) MX2009000359A (es)
NZ (1) NZ574717A (es)
SG (1) SG173369A1 (es)
WO (1) WO2008008772A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741849B2 (en) 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
ES2594281T3 (es) 2007-01-10 2016-12-19 Purdue Research Foundation Inhibidores polipeptídicos de HSP27 quinasa y usos de los mismos
EP3375451A1 (en) * 2008-08-25 2018-09-19 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
KR101965255B1 (ko) 2008-12-10 2019-04-03 퍼듀 리서치 파운데이션 키나아제의 세포-침투성 펩티드-기초된 저해물질
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2013134177A1 (en) * 2012-03-05 2013-09-12 Capstone Therapeutics Corp. Methods and compositions for improving spinal surgery outcomes
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
KR102166543B1 (ko) * 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
US20170275650A1 (en) * 2014-07-22 2017-09-28 The Regents Of The University Of California Endosomal escape domains for delivery of macromolecules into cells
KR101667900B1 (ko) * 2016-01-15 2016-10-21 테고사이언스 (주) 켈로이드성 피부 또는 켈로이드 흉터 진단용 바이오마커 단백질 및 이의 이용

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5280038A (en) * 1992-03-13 1994-01-18 Virginia Commonwealth University Histidine as a protective agent in cardiac surgery and myocardial ischemic syndrome
US5985635A (en) * 1996-11-15 1999-11-16 Incyte Pharmaceuticals, Inc. Nucleic acids encoding novel human serine/threonine protein kinases
US7556722B2 (en) * 1996-11-22 2009-07-07 Metzger Hubert F Electroplating apparatus
US6475490B1 (en) * 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
EP2301563A3 (en) * 2001-08-23 2011-08-10 Board Of Regents Arizona HSP20 peptides
US20030190364A1 (en) * 2002-04-01 2003-10-09 Alyssa Panitch Biological affinity based delivery systems
ES2338350T3 (es) * 2003-02-21 2010-05-06 Arizona Board Of Regents Utilizacion de hsp20 para estimular la cicatrizacion de heridas y/o para reducir la formacion de cicatrices.
US8124579B2 (en) * 2003-10-17 2012-02-28 Arizona Board Of Regents Heat shock protein 20-related polypeptides and uses therefor
JP2009033589A (ja) * 2007-07-30 2009-02-12 Ricoh Co Ltd 画像形成装置、プログラムおよび記録媒体

Also Published As

Publication number Publication date
US20110028398A1 (en) 2011-02-03
MX2009000359A (es) 2009-05-08
NZ574717A (en) 2011-11-25
EP2051727A4 (en) 2012-03-14
AU2007272578A1 (en) 2008-01-17
KR20090023685A (ko) 2009-03-05
EP2051727A2 (en) 2009-04-29
BRPI0714383A2 (pt) 2013-04-30
AU2007272578B2 (en) 2012-11-08
JP5048772B2 (ja) 2012-10-17
JP2009543800A (ja) 2009-12-10
CA2657263A1 (en) 2008-01-17
DOP2009000005A (es) 2009-04-30
WO2008008772A3 (en) 2008-10-16
WO2008008772A2 (en) 2008-01-17
KR101267217B1 (ko) 2013-05-31
SG173369A1 (en) 2011-08-29

Similar Documents

Publication Publication Date Title
CR10552A (es) Metodos para tratar y limitar trastornos fibroticos y queloides
CL2020002018A1 (es) Composiciones para modular la expresión de c9orf72. (divisional solicitud 201803582)
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
CR20170359A (es) Oligómetros antisentido de tau y usos de estos
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
IN2012DN02018A (es)
BRPI0712607A8 (pt) métodos de tratamento de acidente vascular cerebral
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA201690745A1 (ru) Способы лечения и предотвращения болезни "трансплантат против хозяина"
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CO2018004684A2 (es) Métodos para tratar la epilepsia
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
ECSP20082339A (es) Moduladores de la expresión de apol1
MX2016010011A (es) Metodos para tratar y prevenir trastornos renales y trastornos del higado graso.
CO2016000671A1 (es) Construcciones de variantes de sirp-alfa y sus usos
WO2013039956A3 (en) Compositions and methods for treating mood disorders
MX2017011018A (es) Inhibicion de la actividad de olig2.
ZA201901367B (en) Inhibition of olig2 activity
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
WO2014106772A3 (ru) Фармацевтическая композиция для лечения гиперплазии предстательной железы